US2023098083A1PendingUtilityA1

Dry powder inhaler

Assignee: MANNKIND CORPPriority: Jan 29, 2016Filed: Nov 9, 2022Published: Mar 30, 2023
Est. expiryJan 29, 2036(~9.5 yrs left)· nominal 20-yr term from priority
A61K 31/658A61M 2202/064A61M 2205/583A61K 31/661A61P 11/00A61K 31/495A61M 2206/14A61M 15/0021A61M 2205/10A61K 9/0075A61K 31/5575A61M 2205/121A61K 36/60A61M 15/0045A61M 15/0028A61K 31/137A61K 9/1617A61M 15/0025A61K 31/473A61M 15/0091A61M 2207/00A61M 2205/128A61P 9/12A61K 31/352A61K 2300/00
79
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A dry powder inhaler including replaceable cartridges containing a dry powder for local or systemic delivery through the pulmonary tract and lungs is disclosed. The inhalers are used with inhalable dry powders, including medicament formulations comprising active agents for local or systemic delivery and for the treatment of diseases such as, pulmonary hypertension, cardiovascular disease, anaphylaxis, diabetes, obesity, cancer, and other diseases, or symptoms associated with these and other diseases, such as nausea, vomiting, pain and inflammation.

Claims

exact text as granted — not AI-modified
1 . A method for treating pulmonary hypertension, the method comprising:
 administering a dry powder composition comprising microcrystalline particles of fumaryl diketopiperazine and treprostinil, wherein the treprostinil content is up to about 20% (w/w) in the composition, and   treating the pulmonary hypertension.   
     
     
         2 . The method of  claim 1 , wherein the administering is by a dry powder inhaler. 
     
     
         3 . The method of  claim 1 , wherein the treprostinil content is from about 0.5% (w/w) to about 10% (w/w). 
     
     
         4 .- 7 . (canceled) 
     
     
         8 . The method of  claim 2 , wherein the dry powder inhaler is configured to have flow conduits with a total resistance to flow in a dosing configuration ranging in value from 0.065 to about 0.200 (kPa)/liter per minute. 
     
     
         9 . The method of  claim 1 , wherein the administering provides a dose of about 1 mg to about 15 mg of the dry powder composition. 
     
     
         10 . The method of  claim 1 , wherein the administering is oral. 
     
     
         11 . The method of  claim 1 , wherein the administering is by inhalation. 
     
     
         12 . The method of  claim 2 , wherein the dry powder inhaler includes a housing and a body, wherein the body comprises a mounting area for a cartridge that includes the dry powder composition, and the body and the housing are movable relative to one another linearly and are operably configured to engage one another by insertion to effectuate the cartridge to be reconfigured to attain an airflow pathway for discharging a powder dose upon an inhalation. 
     
     
         13 . A dry powder comprising microcrystalline particles of fumaryl diketopiperazine and treprostinil, wherein the dry powder composition is formed by spray drying a solution including about 0.2 to about 1.0 w/w treprostinil in ethyl alcohol and a suspension of FDKP microcrystallites.

Join the waitlist — get patent alerts

Track US2023098083A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.